A leading cannabis real estate investment trust (REIT) firm has signed a long-term deal with Green Thumb Industries (GTI) (CSE:GTII,OTCQX:GTBIF).

On Monday (February 3), Innovative Industrial Properties (IIP) (NYSE:IIPR) confirmed that its new partnership with the Illinois-based multi-state operator (MSO) will begin with a sale-leaseback transaction for a processing facility in Toledo, Ohio.


This isn’t the first agreement completed between the two firms, as last year the duo came together for a cultivation and processing facility sale-leaseback agreement in Danville, Pennsylvania.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Ben Kovler, GTI’s founder and CEO, said in a statement that the funds for the deal in Ohio will be used for expansion purposes.

“IIP provides a flexible real estate capital solution that effectively addresses our expansion needs at the processing facility in Toledo,” the GTI executive said.

The total agreed sum for the facility is US$7.2 million, given that GTI completes a list of undisclosed improvements to the operation. If the facility work is not completed, IIP will only pay US$2.9 million, according to the joint announcement from the US firms.

“GTI continues to distinguish itself with its cannabis product offerings and dedication to patient experience and right to well-being, providing safe, high quality cannabis products in a compassionate environment,” said Paul Smithers, president and CEO of IIP.

The market offered differing takes for each company on the announcement. Shares of IIP soared at open, and as of 1:30 p.m. EST were trading at US$92.74, representing an increase of 3.7 percent.

On the other hand, GTI shares dragged in Monday’s trading session with a 3.4 percent drop in value, resulting in a price per share of US$12.22.

IIP has quickly embedded itself as a capital solution for cannabis companies facing the harsher realities of the capital markets, thanks to the REIT strategy.

The REIT company has seen this interest reflected in its share price so far this year, experiencing a jump in value of over 20 percent. While most of the cannabis universe has struggled recently, IIP has continued to grow and offer investors access to a cannabis play while remaining compliant with regulations for the New York Stock Exchange.

stock chart for IIP

In a previous interview with the Investing News Network (INN), Smithers said investors feel more comfortable with the company as it adheres strictly to real estate operations. With every deal completed, IIP does not obtain a stake in the cannabis company participant.

“We’re strictly a real estate company and I think there’s a certain group of investors that like that. It’s a little more stability than a company that is perhaps growing,” said Smithers.

MSOs in the US have embraced the REIT model, with fellow MSO Cresco Labs (CSE:CL,OTCQX:CRLBF) completing separate agreements with both IIP and GreenAcreage Real Estate.

“It becomes a higher operating cost that that company will incur for the term of the lease and some of these are 15 years, and they’re not very cheap,” Mike Regan, an analyst with Marijuana Business Daily’s Investor Intelligence, previously told INN. “But that’s still cheaper than going out of business.”

Shares of the REIT company have been added to the recently debuted Medical Cannabis & Wellness UCITS ETF (XETRA:CBDX). The fund trades in Europe and offers investors established cannabis plays with no connection to the recreational space in North America.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

A middling Canadian cannabis producer announced an executive turnover plan this week after receiving a critical investor letter in September.

Meanwhile, a Canadian exchange-traded fund (ETF) company released lists of new additions to both of its cannabis funds as part of its quarterly rebalancing.

Keep reading... Show less
  • The Cannabis Derivatives are derived from Avicanna’s cultivation and extraction infrastructure in Santa Marta, Colombia designed to supply partner companies and the manufacture of Avicanna’s own finished products.

Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“ SMGH ”), it has completed a commercial exports of CBD Isolate and CBD full spectrum psychoactive cannabis resin (the “ Cannabis Derivatives ”) to a leading Chilean homeopathic and naturopathic pharmaceutical company.

The Cannabis Derivatives, branded as Aureus™, are cultivated, extracted, and manufactured by SMGH. In addition, for Avicanna’s global input needs, SMGH also supplies other pharmaceutical and cosmetics companies with cannabinoids including CBD, THC, and rare cannabinoids such as CBG in addition to supplying global cultivation companies with standardized and feminized seeds. This new export to Chile is a recurring order and part of on-going relationship with an established homeopathic Chilean company.

Keep reading... Show less

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2022 ended September 30, 2021 before financial markets open on November 5, 2021 .

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the opening of a new Sunnyside dispensary in Wyomissing, Pennsylvania. Wyomissing will be Cresco Labs’ fifth dispensary in Pennsylvania and 38 th nationwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021006075/en/

Keep reading... Show less

The world of cannabis consumption is set to change radically, thanks in large part to the advancement of state-of-the-art research on the plant itself.

Medical cannabis products have already allowed many new users to discover the plant’s potential, but decisive research will help build a foundation for more sophisticated medical offerings.

Keep reading... Show less